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Abstract
Candida and Aspergillus spp. are the most common agents responsible for invasive fungal infections in children.
They are associated with a high mortality and morbidity rate as well as high health care costs. An important
increase in their incidence has been observed during the past two decades. In infants and children, invasive
candidiasis is five times more frequent than invasive aspergillosis. Candida sp. represents the third most common
agent found in healthcare-associated bloodstream infections in children. Invasive aspergillosis is more often
associated with hematological malignancies and solid tumors. Recommendations concerning prophylactic
treatment for invasive aspergillosis have been recently published by the Infectious Diseases Society of America.
Candida albicans is the main Candida sp. associated with invasive candidiasis in children, even if a strong trend
toward the emergence of Candida non-albicans has been observed. The epidemiology and the risk factors for
invasive fungal infections are quite different if considering previously healthy children hospitalized in the pediatric
intensive care unit, or children with a malignancy or a severe hematological disease (leukemia). In children, the
mortality rate for invasive aspergillosis is 2.5 to 3.5 higher than for invasive candidiasis (respectively 70% vs. 20%
and 30%).
Introduction
Candida and Aspergillus spp. are the most common
agents responsible for invasive fungal infections (IFI) in
children. They are associated with a high mortality and
morbidity rate as well as high health care costs. Their
incidence has dramatically increased within the past two
decades [1-3]. In children, invasive Candida infection
(ICI) is five times more frequent than invasive Aspergil-
lus infection (IAI). Candida spp. is the third most com-
mon agent implicated in healthcare-associated
bloodstream infections in children [4-8]. IAI is more
often associated with hematological malignancies and
solid tumors. Strong recommendations concerning pro-
phylactic treatment for IAI have been published [9].
Although Candida albicans is still the main Candida sp.
associated with ICI in children, a strong trend toward
the emergence of Candida non-albicans has been
observed. This could be linked to the use of fluconazole
prophylaxis in some patients [2,4]. The epidemiology/
risk factors for IFI are quite different between previously
healthy children hospitalized in the pediatric intensive
care unit (PICU) and children whose hospitalization is
related to malignancy or a severe hematological disease
(leukemia). Indeed, in the second group, the reported
incidence is approximately 5% with a mortality rate of
approximately 60% [10]. The crude mortality of patients
with IFI is 32% [11]. The mortality rate due to IAI in
children is approximately 70% despite appropriate treat-
ment, whereas it is between 20% and 30% for ICI [5,12].
Fungal infections and nosocomial infections
In France, a 1-day national survey of nosocomial infec-
tions performed in 2001 included 21,596 children
younger than aged 18 years (7.1% of all hospitalized
children) [13]. Overall, 2.4% presented with a nosoco-
mial infection (1.2% for newborns and 3.3% for chil-
dren). ICI, in this study, accounted for 4.4% of all
infections, regardless of which unit the children were
hospitalized in. The rate of nosocomial infections in
children hospitalized in PICUs was approximately 15%
[13]. Posfay-Barbe et al. reported a Candida infection
rate of 10% in children younger than aged 18 years in
the United States, regardless of age and hospital unit
[11]. In 1999, Richards et al. [8] showed that Candida
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PICUs in the United States. An Israeli study [14] found
Candida spp in 14.4% of bloodstream infections in
PICUs. Aspergillus was found in 0.5% of lung infections
and 0.1% of sepsis [8].
Invasive candidiasis in the PICU
Epidemiology
ICI in the PICU presents as candidemia or disseminated
candidiasis (kidney, liver, eye, etc.). In 2000, a large U.S.
study on the epidemiology and outcome of hospitalized
adults and children with candidemia showed a higher
candidemia rate among hospitalized children than adults
(43 vs. 30 cases per 100,000 admissions, respectively)
[7]. Dutta et al. reported an increase in the incidence of
candidemia in their institution (Houston, Texas), rising
from 0.06 to 0.3 per 1,000 inpatients from 2000 to 2009
(with an increase from to 2000 to 2004 followed by a
stabilization after 2005) [15].
ICI is a very severe disease with an attributable mor-
tality in children between 20% to 30% [5,12], and a mor-
tality rate among children with ICI between 16% to 31%
[5]. Depending on the study, Candida is either the sec-
ond, third, or fourth causative agent for sepsis in hospi-
talized children, after coagulase negative Staphylococci,
enterococci, and Staphylococcus aureus [4-8]. Singhi et
al. reported recently that Candida spp colonization
occurs in approximately 70% of pediatric patients in the
PICU [16]. The risk of colonization is particularly
important in small children [17]. In the report by Zaou-
tis et al., the incidence of candidemia in the PICU was
3.5 per 1,000 admissions [3].
Candida albicans is more predominant in children
than in adults. Moreover, Candida albicans remains, in
various studies, the most common fungal agent
associated with ICI regardless of age (55%), followed by
C. parapsilosis (17.5%), C. tropicalis (10%), Cg l a b r a t a ,
and krusei (2-3% each) [4]. Although Candida albicans
is the main Candida species in children, some strains
are associated with specific conditions: Cg l a b r a t a
among surgical patients or those with a central venous
line; C. tropicalis among patients with malignant disease
or neutropenia; and C. parapsilosis among infants or
those on parenteral nutrition.
Pfaller [18] reported data on blood samples from 79
medical centers throughout the world and confirmed
these results in 256 children aged 0 to 19 years: 50% of
patients experienced infection with C. albicans,2 8 . 5 %
with C. parapsilosis, 12.9% with C. tropicalis, 2% with C.
glabrata, and 0.8% with C. krusei.
Risk factors
Hospitalization in the PICU represents a risk factor for
ICI. Other risk factors include presence of a central
venous line, parenteral nutrition, preexisting bacterial
infection, immunocompromised status, recent surgery,
dialysis, prolonged use of vancomycin, and mechanical
ventilation [6]. Table 1 summarizes the risk factors for
developing ICI in children hospitalized in the PICU.
These risk factors can coexist. The role of the central
venous line in the occurrence of disseminated candidia-
sis is well known; it increases threefold the risk for
developing a disseminated infection (odds ratio [OR] =
3.0; 95% confidence interval [CI], 1.2-7.8; p = 0.02) for
patients who have a central venous line in place for 3
days [19]. The recommendations given by the Infectious
Diseases Society of America are very clear regarding
central line replacement in case of ICI: “Central venous
catheters should be removed when candidemia is docu-
mented, if at all possible”[9]. Predicting the risk for chil-
dren to develop candidemia in the PICU poses an
Table 1 Risk factors for Invasive Candida Infection in children (from [3])
Risk factors for invasive candidiasis Unadjusted odds ratio 95% Confidence interval
Malignancy 3.22 1.36-7.6
Presence of a central venous catheter 13.4 4.8-37.42
Presence of a arterial catheter 1.77 1.02-3.06
Receipt of total parenteral nutrition 5.3 2.8-10.05
Neutropenia within 15 days 5.58 1.12-27.79
Non-candidal blood stream infection within 15 days 2.47 1.35-4.52
Receipt of antifungal agents within 15 days 2.86 1.44-5.66
Receipt of antibiotics within 15 days 5.44 1.87-15.77
Parenteral or oral vancomycin during 1-3 days 2.56 1.27-5.16
Parenteral or oral vancomycin ≥4 days 3.17 1.73-5.82
Extended-spectrum cephalosporins ≥4 days 2.31 1.26-4.22
Carbapenems ≥4 days 3.29 1.1-9.89
Aminoglycosides 2.09 1.17-3.74
Agents covering anaerobic organisms ≥4 days
a 2.3 1.29-4.11
aIncluding ampicillin sulbactam, clindamycin, imipenem, meropenem, metronidazole, and ticarcillin-clavulanate
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in 101 children hospitalized in the PICU, it has been
shown recently [3] that the risk of ICI in this population
increased from 10% (malignancy + central venous line +
more than 3 days of vancomycine) to 46% (antibiotics
with anti-anaerobic activity + malignancy + central
venous line + total parenteral nutrition + more than 3
days of vancomycine). Based on data from studies in
adult patients, some authors have suggested using anti-
fungal prophylaxis in patients for whom the risk of can-
didemia is higher than 10% [20].
There is an association between ICI and Candida
colonization. Singhi et al. [16] noted a positive correla-
tion (p = 0.033) between colonization and candidemia
among PICU patients, regardless of site of colonization.
Colonization was four times more likely in patients with
a central venous line. Authors compared 20 patients
with candidemia and 45 patients without candidemia.
Eighteen of the infected patients were colonized with
Candida (90%), whereas only 27 of the noninfected
patients were colonized (OR = 6; 95% CI, 1.2-29.1; p =
0.03). In the literature regarding adults, many publica-
tions have reported scores or indexes based on localiza-
tion of Candida colonization, and the presence or not
of clinical signs, to identify people at risk of developing
ICI [21-23]. Pittet et al. showed the value of using a
Candida colonization index (ratio of the number of dis-
tinct, non-blood, body sites, screening positive for Can-
dida spp to the total number of distinct body sites
tested) to identify colonized patients who should be
treated preemptively with antifungal therapy [23]. The
authors chose a cutoff value ≥0.5 for their index.
Although the sensitivity of the proposed index was high
(100%), its positive predictive value was poor (66%).
Patients enrolled in the study by Pittet et al. were all
from surgical units. It is possible that this colonization
index is more useful in a unit with a known high inci-
dence of candidemia. In units with a low incidence rate
(medical ICU for example), associating clinical or/and
biological signs with this index could enhance its accu-
racy. It would be legitimate to take a similar approach
in children to offer more reliable, early preemptive or
probabilistic treatments. Such studies in children are not
currently available and should be done. Lortholary et al.
reported a risk of being infected with a strain presenting
reduced susceptibility to an antifungal therapy (Caspo-
fungin or Fluconazole), in cases of recent exposure to
one of these two drugs [24].
Mortality
In children, candidemia was associated with a 10%
increase in mortality (95% CI, 6.2-13.8%), a 21.1-day
increase in the average length of stay (95% CI, 14.4-27.8
days), and an average increase in total hospital costs of
$92,266 per patient (95% CI, $65,058-119,474) [7]. The
mortality rate for candidemia was 30% for children and
reached 43-54% in infants [7]. As shown in Figure 1, the
m o r t a l i t yr a t ed u et oCandida infection is highly corre-
lated to the species of Candida and the child’s age [6].
Overall, it should be noted that mortality rates appear
higher in older patients regardless of the strain involved.
Some authors reported that ICI linked to C. parapsilosis
appeared to be less aggressive than cases linked to C.
albicans (27% vs. 47% mortality rate in children younger
than 13 years; n = 144) [6]. However, Dutta et al. [15]
showed, in a series of 108 children, no difference in
terms of 30-day mortality between strains of Candida.
Hospitalization in the PICU at the time of diagnosis of
invasive candidiasis and the presence of an arterial
catheter were independent risk factors for increased
mortality [25]. High mortality rates have been observed
in specific populations, and some authors have identified
ethnic origin as a possible risk factor for developing ICI,
especially in Filipino patients [26]. No other studies
have confirmed these data.
Candidiasis and children in pediatric oncology
In pediatric oncology units, there often are more yeast
infections than mold infections. In the study by Mor et
al. [10], concerning 75 children with IFI and malignancy
pathologies, positive blood cultures for yeast were
obtained in 100% of infected cases. The main underlying
diagnoses associated with yeast infections were acute
myeloid leukemia (AML) and neuroblastoma (26.7%
each); five patients (older than aged 15 years, with inva-
sive yeast infections) underwent hematologic stem cell
transplantation (HSCT). Sung et al. [27] performed a sur-
vey of the available data from the pediatric cancer popu-
lation (more specifically patients with AML) and IFI.
They reported that during the induction and consolida-
tion phases of treatment, respectively, 10% and 6% of
children developed Candida infection. In this study, Can-
dida spp. represented 25.9% of infection-related mortality
(overall 11% ± -2%). The authors observed that in the
case of intensive timing induction phase, compared with
standard timing induction, the rate of yeast infections
can increase 2.5-fold (8.4% vs. 19%; p < 0.01). So, the tim-
ing of the chemotherapy, regardless of dose, has an
impact on the patient’s risk for developing IFI. In chil-
dren hospitalized in the PICU, the existence of an under-
lying malignancy is very important and increases from
17.5% to 46% the predicted probability of ICI [3].
Invasive Aspergillosis infections in PICU
There is little specific data available in the literature
regarding children with IAI [5]. Furthermore, the avail-
able data are not homogeneous (definition, incidence,
concerned population) making analysis difficult. Clear
incidence of IAI in children with or without a hematolo-
gic underlying disease, or in the PICU, is not easy to
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the incidence in a specific subpopulation, whereas other
papers give the proportion of children with IAI in speci-
fic conditions, i.e., presence of an underlying disease
(such as AML or acute lymphoid lymphoblastic, for
example). Another limitation is that definitions and care
have changed over the decades. The largest study con-
cerns 139 cases of IAI in children and only reports data
until July 1, 2005 [1].
Epidemiology
Studies report a three- to fourfold increase in the inci-
dence of IAI during the past decade [5,28], mainly attri-
butable to the improvement of the quality of treatment
and the survival rate of immunocompromised patients.
In 2006, the annual incidence of IAI in children was
0.4% in the United States. Three quarters of these
patients were immunosuppressed or suffered from onco-
logical diseases [5]. In 2008, Crassard et al. [29] pub-
lished a series of 24 cases of proven or probable IAI in
children hospitalized in a pediatric hematologic depart-
ment during a period of 15 years (1986-2000). Interest-
ingly, the median interval between the onset of the
malignancy and the diagnosis of IAI was 8.5 months.
Fifty percent of infected patients had ALL or AML. Ten
children underwent HSCT before the occurrence of IAI.
Overall, 15 children (62.5%) died. The mortality attribu-
table to IAI was estimated to be 37.5% (9 children), 60%
of overall deaths. The incidence of IA varied according
to the underlying disease: 5.35% in AML, 1.5% in ALL.
Other studies reported the same variation in incidence
of IAI according to the underlying disease: 4% in AML
and 1% in ALL for Abbasi et al. [30], and 3.7% in AML
and 0.6% in ALL for Zaoutis et al. [31].
There are conflicting results in the literature regarding
the most commonly identified species of Aspergillus in
pediatric IAI. The most common strains observed in the
pediatric population are A. fumigatus, A. nidulans, A.
f l a v u s ,A .t e r r e u s ,a n dA. niger. The largest contempor-
ary study reporting IAI in children showed, as reported
in adults series, A. fumigatus as the first causative agent
in this disease (Figure 2) [1]. A. flavus was considered as
the first causative organism in two previous studies
[32,33]. In children, A. fumigatus seems to be the most
common species encountered in the pulmonary form of
the disease. A. flavus is predominantly found in skin
infections [1]. Specific consideration must be given to A.
niger whose incidence can reach 6.5% in septic granulo-
matous disease [31].
The most frequent localization was the lung, ranging
from 59% to 91.6% of infections [1,30,33,34]. Walmsey
reported predominance of up to 41% for IAI in skin
lesions [33]. However, this was not confirmed by others
publications, which found respectively 10% [1] and 20%
[30] of cutaneous aspergillosis.
More anecdotic localizations (but not necessarily less
dangerous or difficult to treat) have been described:
Figure 1 Mortality associated with type of Candida spp. among patients with candidemia younger (n = 144) and older (n = 1,447)
than 13 years [6].
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blood, and eye. Dotis et al. performed a systematic
review of the literature for children with central nervous
system Aspergillosis [35], identifying 90 cases since 1950.
When considering children of 1 year or more, leukaemia
(ALL statistically more frequently than AML) was the
predominant underlying condition, followed by solid
tumors, liver transplantation, chronic granulomatous
disease, other hematological disorders, and various other
conditions. Figures 3 and 4 summarize the underlying
conditions encountered in the 139 cases of IAI reported
by Burgos et al. [1]
Risk factors for IA
Risk factors for IAI are well known in both the adult
and pediatric population. It is fundamental to under-
stand that immunocompromised children can contract
community- or hospital-acquired infections (source:
construction work, renovation, air conditioning system
contaminated). Risks factor include presence of several
underlying diseases and their treatments,: hematologic
malignancies, either primary or relapse, allogeneic bone
marrow transplantation [34]; granulocytopenia, corticos-
teroids for malignancy but also autoimmune disease,
immunosuppressive therapies, immunodeficiencies, such
as chronic granulomatous disease, severe combined
immunodeficiency, and organ transplantation, such as
heart-lung transplantation [36]. There is evidence in the
literature that the risk of IAI increases with higher doses
of steroids (most often used in bone marrow transplan-
tation) notably beyond a dose of prednisone > 2 mg/kg/j
[34]. Cushing syndrome because of its endogenous high
secretion of cortisol can favor development of IA [36].
Some risk factors, such as persistent neutropenia, CMV
infection, prolonged antibiotic administration, viral
respiratory infection, HIV infection, and prior coloniza-
tion with Aspergillus, are confounding factors with hos-
pitalization in PICU or with the underlying malignancy
itself [28]. Patients with AML and relapsed ALL are par-
ticularly at risk for IAI [31].
Mortality
Within the past decade in the United States, there has
been a 357% increase in deaths related to IAI, regardless
of the patient’s age [34]. Risk factors for overall mortal-
ity in pediatric patients with IAI are summarized in
Table 2. Patients with IAI have a 20% increase in mor-
tality rate, a 13.5-fold increase in relative risk for death.
Paediatric patients with IAI had a longer median length
of hospital stay than immunocompromised children
without IA (respectively 16 days and 3 days) [31]. Even
with appropriate treatment, therapeutic response to IAI
rarely exceeds 50%. In the study by Burgos, the mortal-
ity rate for treated patients reached 52.5% [1]. Lin et al.
[37] reported an overall IAI mortality rate of 58% when
including patients of all ages and 68% in patients
younger than aged 20 years. The mortality rate varied
according to the underlying disease: 88.1% in cases of
disseminated aspergillosis or CNS involvement, 86.7% in
cases of bone marrow transplantation, 85.7% in HIV
infection or AIDS. Highly active antiretroviral therapy
(HAART) has profoundly transformed the incidence and
prognosis of IAI in patients with HIV and AIDS.
The overall mortality rate for children with AML and
ALL is quite low (respectively 3% and 1%). However, if
children with AML or ALL develop IAI, the mortality
Figure 2 Aspergillus species encountered in invasive aspergillosis in 139 children [1].
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(respectively to 20% and 21%) [5,31].
CNS aspergillosis-related mortality is usually reported
as exceeding 80% [37]. However, in the study by Dotis
et al. [35], the overall mortality of cases published in the
literature since the 1950s was 65.4% with a strong differ-
ence between the periods before and after 1990 (respec-
tively 82.8% vs. 39.5%). This may be due to improved
patient care. Table 2 summarizes the risk factors for
mortality in IAI identified by Burgos et al. [1].
Figure 3 Underlying condition of the 139 cases of invasive aspergillosis in the study by Burgos et al. [1].
Figure 4 Details of the 87 underlying haematological disease in children with invasive aspergillosis in the study by Burgos et al. [1].
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The frequency and severity of IFI in children has
increased steadily during the past 20 years. This is due to
t h eh i g h e rp r e v a l e n c eo fs u s c e p t i b l eh o s t sw h oa r ek e p t
alive with more aggressive therapy (cytotoxic, immuno-
suppressive), the specific treatment of hematopoietic
stem cell transplantation, and the use of broad-spectrum
antibiotics. Candida spp.a n dAspergillus spp.a r et h e
most frequently identified fungi in children. The attribu-
table mortality of each of these two invasive infections
remains different mainly because the affected patients are
different (more hematologic malignancies in patients
with Aspergillus infection). Preemptive therapy has been
well defined in cases of IAI, and recommendations have
been provided by the IDSA [9]. The real challenge
remains to identify patients with a high risk of invasive
candidiasis in the PICU to propose targeted prophylaxis.
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